EG24380A - Granule formulation - Google Patents

Granule formulation

Info

Publication number: EG24380A
Authority: EG; Egypt
Prior art keywords: granule formulation; granule; formulation; relates; present
Prior art date: 2001-10-26

Application number

EG2002101164A

Other languages

English (en)

Inventor

Down Brian

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-23

Publication date

2009-04-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-23 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2009-04-05 Application granted granted Critical

2009-04-05 Publication of EG24380A publication Critical patent/EG24380A/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

EG2002101164A 2001-10-26 2002-10-23 Granule formulation EG24380A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33954901P	2001-10-26	2001-10-26

Publications (1)

Publication Number	Publication Date
EG24380A true EG24380A (en)	2009-04-05

Family

ID=23329547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG2002101164A EG24380A (en)	2001-10-26	2002-10-23	Granule formulation

Country Status (26)

Country	Link
US (2)	US20030096840A1 (xx)
EP (1)	EP1441701B1 (xx)
JP (1)	JP4420671B2 (xx)
KR (1)	KR101094084B1 (xx)
CN (1)	CN100591329C (xx)
AT (1)	ATE385781T1 (xx)
AU (1)	AU2002333134B2 (xx)
BR (1)	BR0213477A (xx)
CA (1)	CA2463947C (xx)
CY (1)	CY1107400T1 (xx)
DE (1)	DE60225040T2 (xx)
DK (1)	DK1441701T3 (xx)
EC (1)	ECSP045082A (xx)
EG (1)	EG24380A (xx)
ES (1)	ES2298431T3 (xx)
HR (1)	HRP20040367B1 (xx)
HU (1)	HUP0401670A3 (xx)
IL (1)	IL161299A0 (xx)
MX (1)	MXPA04003856A (xx)
MY (1)	MY148466A (xx)
NO (1)	NO20042167L (xx)
PE (1)	PE20030638A1 (xx)
PT (1)	PT1441701E (xx)
SI (1)	SI1441701T1 (xx)
WO (1)	WO2003035036A1 (xx)
ZA (1)	ZA200402584B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040192660A1 (en) *	2003-03-12	2004-09-30	Mullally John P.	Protocol for improving vision
CA2595791C (en) *	2005-03-16	2013-10-08	Meda Pharma Gmbh & Co. Kg	The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1954298A4 (en)	2005-11-28	2012-10-31	Imaginot Pty Ltd	DISPENSING SYSTEM FOR ORAL THERAPEUTIC CONNECTION
PL1976522T5 (pl)	2005-12-30	2019-12-31	Krka Tovarna Zdravil, D.D., Novo Mesto	Kompozycja farmaceutyczna zawierająca montelukast
JP2009526047A (ja) *	2006-02-09	2009-07-16	テバファーマシューティカルインダストリーズリミティド	モンテルカストナトリウムの安定な医薬製剤
EP2066302A2 (en)	2006-09-26	2009-06-10	Taro Pharmaceuticals North America, Inc.	Stabilizing compositions for antibiotics and methods of use
EP2262536A4 (en) *	2008-03-26	2013-07-03	Taro Pharmaceuticals North America Inc	STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS
LT3225249T (lt)	2008-05-21	2019-01-10	Ferring B.V.	Burnoje disperguojamas desmopresinas, skirtas pirminio miego periodo, nepertraukiamo nikturija, pailginimui
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
WO2009153305A2 (en) *	2008-06-19	2009-12-23	Sandoz Ag	Pharmaceutical compositions of montelukast sodium
BRPI0912589A2 (pt) *	2008-08-18	2015-10-13	Mitsubishi Shoji Foodtech Co Ltd	"excipiente para comprimidos composto de novo manitol esférico"
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
CN104606128B (zh)	2010-03-29	2018-02-23	辉凌公司	一种快速溶解药物组合物
FR2967066B1 (fr) *	2010-11-04	2013-06-14	Ethypharm Sa	Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) *	2011-01-27	2012-01-11	海南美大制药有限公司	孟鲁司特钠脂质体固体制剂
BR112014001760A2 (pt)	2011-07-26	2017-03-07	Sun Pharma Advanced Res Co Ltd	antagonistas de leucotrieno cisteínico
US9731018B2 (en)	2011-09-16	2017-08-15	Ferring B.V.	Fast dissolving pharmaceutical composition
WO2013077829A1 (en)	2011-11-21	2013-05-30	Mahmut Bilgic	Water-soluble pharmaceutical granules
WO2014009241A1 (en)	2012-07-12	2014-01-16	Ferring B.V.	Diclofenac formulations
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) *	2012-09-12	2014-03-13	Glenmark Generics Ltd.	Stable pharmaceutical composition of saxagliptin
CN103520129B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	一种孟鲁斯特钠脉冲释放制剂
CN103520130B (zh) *	2013-10-15	2020-08-04	天垚医药科技发展（上海）有限公司	孟鲁斯特钠择时控释片及其制备方法
CN103520136B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	孟鲁斯特钠脉冲胶囊及其制备方法
CN104644564A (zh) *	2013-11-25	2015-05-27	天津汉瑞药业有限公司	一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) *	2013-12-18	2018-05-29	北京华禧联合科技发展有限公司	一种孟鲁司特钠口腔崩解片及其制备方法
WO2015110394A1 (en)	2014-01-22	2015-07-30	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN103720672B (zh) *	2014-01-26	2016-03-16	新疆特丰药业股份有限公司	孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) *	2014-02-13	2017-09-29	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
KR101892340B1 (ko) *	2015-03-13	2018-08-27	경희대학교 산학협력단	몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) *	2015-04-20	2019-03-27	高田製薬株式会社	モンテルカストナトリウム顆粒製剤
CN107595783A (zh) *	2017-06-01	2018-01-19	合肥远志医药科技开发有限公司	一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) *	2017-11-29	2019-06-04	扬子江药业集团有限公司	一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) *	2018-08-01	2020-02-14	北京万全德众医药生物技术有限公司	一种孟鲁司特钠药物组合物
KR20210042412A (ko)	2018-09-06	2021-04-19	주식회사 이노파마스크린	천식 또는 파킨슨병 치료를 위한 방법 및 조성물
CN111110679A (zh) *	2018-10-31	2020-05-08	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) *	2020-01-19	2020-06-09	安徽省先锋制药有限公司	一种孟鲁司特钠颗粒制剂方法
US11844792B2 (en) *	2020-07-10	2023-12-19	Sean Downing	Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) *	2020-07-29	2022-05-06	浙江诺得药业有限公司	一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114224847B (zh) *	2021-12-07	2023-09-15	哈尔滨珍宝制药有限公司	一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) *	2022-02-24	2022-05-03	佑华医药科技有限公司	一种孟鲁司特钠颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1561301A (en) *	1976-01-02	1980-02-20	Beecham Group Ltd	Orally administrable pharmaceutical composition
NZ230763A (en) *	1988-09-27	1991-10-25	Takeda Chemical Industries Ltd	Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
DE68916497T2 (de) *	1988-09-30	1994-11-17	Rhone Poulenc Rorer Ltd	Pharmazeutisches Granulat.
EP0390435B1 (en) *	1989-03-29	1994-01-05	Takeda Chemical Industries, Ltd.	Vitamin B group compound composition and its production
JP2800242B2 (ja)	1989-03-30	1998-09-21	大正製薬株式会社	粒剤の製造方法
US5565473A (en) *	1990-10-12	1996-10-15	Merck Frosst Canada, Inc.	Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja)	1991-03-07	1998-11-05	武田薬品工業株式会社	有核散剤およびその製造方法
JPH0967247A (ja)	1995-08-31	1997-03-11	Taisho Pharmaceut Co Ltd	均一な微粒子製剤の製造方法
WO1997016173A1 (en) *	1995-11-02	1997-05-09	Merck Frosst Canada Inc.	New technology for wet granulation
US5869098A (en) *	1997-08-20	1999-02-09	Fuisz Technologies Ltd.	Fast-dissolving comestible units formed under high-speed/high-pressure conditions
SK286103B6 (sk)	1997-12-23	2008-03-05	Schering Corporation	Farmaceutický prostriedok na liečenie respiračných a kožných ochorení s obsahom aspoň jedného antagonistu leukotriénu a aspoň jedného antihistaminikaa jeho použitie
US6224907B1 (en) *	1998-03-06	2001-05-01	Alza Corporation	Anti-asthma therapy
US6221880B1 (en) *	1998-10-09	2001-04-24	Schering Corporation	Composition and method for treating allergic diseases
US6103735A (en) *	1998-10-09	2000-08-15	Schering Corporation	Composition and method for treating allergic diseases
AT413647B (de)	1998-11-26	2006-04-15	Sandoz Ag	Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) *	2000-01-14	2002-12-10	Osmotica Corp.	Osmotic device within an osmotic device
US20030031720A1 (en) *	2000-02-24	2003-02-13	Tobias Laich	Method for producing pharmaceutical dosage forms
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form

2002
- 2002-10-17 MY MYPI20023875A patent/MY148466A/en unknown
- 2002-10-22 BR BR0213477-2A patent/BR0213477A/pt active Pending
- 2002-10-22 WO PCT/CA2002/001604 patent/WO2003035036A1/en active IP Right Grant
- 2002-10-22 SI SI200230670T patent/SI1441701T1/sl unknown
- 2002-10-22 PT PT02801836T patent/PT1441701E/pt unknown
- 2002-10-22 MX MXPA04003856A patent/MXPA04003856A/es active IP Right Grant
- 2002-10-22 CN CN02821212A patent/CN100591329C/zh not_active Expired - Lifetime
- 2002-10-22 HU HU0401670A patent/HUP0401670A3/hu unknown
- 2002-10-22 KR KR1020047006095A patent/KR101094084B1/ko active IP Right Review Request
- 2002-10-22 JP JP2003537603A patent/JP4420671B2/ja not_active Expired - Lifetime
- 2002-10-22 AU AU2002333134A patent/AU2002333134B2/en not_active Expired
- 2002-10-22 DE DE60225040T patent/DE60225040T2/de not_active Expired - Lifetime
- 2002-10-22 EP EP02801836A patent/EP1441701B1/en not_active Revoked
- 2002-10-22 AT AT02801836T patent/ATE385781T1/de active
- 2002-10-22 ES ES02801836T patent/ES2298431T3/es not_active Expired - Lifetime
- 2002-10-22 CA CA002463947A patent/CA2463947C/en not_active Expired - Lifetime
- 2002-10-22 IL IL16129902A patent/IL161299A0/xx unknown
- 2002-10-22 DK DK02801836T patent/DK1441701T3/da active
- 2002-10-23 EG EG2002101164A patent/EG24380A/xx active
- 2002-10-24 PE PE2002001047A patent/PE20030638A1/es active IP Right Grant
- 2002-10-24 US US10/279,595 patent/US20030096840A1/en not_active Abandoned
2004
- 2004-04-01 ZA ZA2004/02584A patent/ZA200402584B/en unknown
- 2004-04-23 HR HRP20040367AA patent/HRP20040367B1/xx not_active IP Right Cessation
- 2004-04-23 EC EC2004005082A patent/ECSP045082A/es unknown
- 2004-05-25 NO NO20042167A patent/NO20042167L/no not_active Application Discontinuation
2008
- 2008-02-07 US US12/069,124 patent/US8007830B2/en not_active Expired - Fee Related
- 2008-04-17 CY CY20081100434T patent/CY1107400T1/el unknown

Also Published As

Publication number	Publication date
ECSP045082A (es)	2004-06-28
SI1441701T1 (sl)	2008-08-31
PE20030638A1 (es)	2003-07-21
HRP20040367A2 (xx)	2005-06-30
US20030096840A1 (en)	2003-05-22
ATE385781T1 (de)	2008-03-15
CA2463947C (en)	2009-05-19
KR20040047961A (ko)	2004-06-05
DE60225040T2 (de)	2009-02-26
EP1441701B1 (en)	2008-02-13
ES2298431T3 (es)	2008-05-16
PT1441701E (pt)	2008-04-07
DK1441701T3 (da)	2008-05-26
US20080131516A1 (en)	2008-06-05
HRP20040367B1 (en)	2012-07-31
KR101094084B1 (ko)	2011-12-15
CN1575163A (zh)	2005-02-02
US8007830B2 (en)	2011-08-30
EP1441701A1 (en)	2004-08-04
HUP0401670A2 (hu)	2008-05-28
IL161299A0 (en)	2004-09-27
JP4420671B2 (ja)	2010-02-24
DE60225040D1 (de)	2008-03-27
AU2002333134B2 (en)	2007-08-02
WO2003035036A1 (en)	2003-05-01
NO20042167L (no)	2004-05-25
CY1107400T1 (el)	2012-12-19
JP2005510497A (ja)	2005-04-21
HUP0401670A3 (en)	2008-08-28
MY148466A (en)	2013-04-30
CA2463947A1 (en)	2003-05-01
MXPA04003856A (es)	2004-07-08
ZA200402584B (en)	2005-06-29
CN100591329C (zh)	2010-02-24
BR0213477A (pt)	2004-11-03

Publication	Publication Date	Title
EG24380A (en)	2009-04-05	Granule formulation
AU3652102A (en)	2002-06-11	Compounds and their uses
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TNSN07235A1 (en)	2008-11-21	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
HK1076605A1 (en)	2006-01-20	Formulations
MXPA04003796A (es)	2004-07-30	Tioacetamidas sustituidas.
IL150257A0 (en)	2002-12-01	Galactomaninan oligosaccharides, pharmaceutical compositions containing the same and methods for the production thereof
HK1077059A1 (en)	2006-02-03	Salt of (s)-pantoprazole and its hydrates (s)-
DK1458377T3 (da)	2006-06-12	Farmaceutiske sammensætninger indeholdende tegaserod
TNSN04206A1 (en)	2007-03-12	Novel perindopril salt and pharmaceutical compositions containing same
PL374080A1 (en)	2005-09-19	Processes for the preparation of fibrinogen
MXPA03010158A (es)	2004-03-10	Sulfonamidas.
WO2002024695A3 (en)	2002-09-19	Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
SE0200657D0 (sv)	2002-03-04	Novel Formulation
MXPA04004090A (es)	2004-07-08	Compuestos substituidos de 1h-quinolin-2-ona.
MXPA04003910A (es)	2004-07-23	Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
DE60212130D1 (en)	2006-07-20	Carvedilolpolymorph
GB0309440D0 (en)	2003-06-04	Quinolone derivatives
MY142077A (en)	2010-08-30	Semi-solid systems containing azetidine derivatives
PL359727A1 (en)	2004-09-06	Crystalline pharmaceutical
TW200603801A (en)	2006-02-01	Novel dialkoxy-imidazopyridines
MXPA03001440A (es)	2003-06-06	Compuestos de trioxepano novedosos.
MXPA04006085A (es)	2004-09-27	Compuestos de isocromano para el tratamiento de trastornos del sistema nervioso central.
GB0109520D0 (en)	2001-06-06	Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors